Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up.
One hundred and ten adult patients with non-Hodgkin's lymphoma (NHL) received an autologous hematopoietic cell transplant (ABMT) from 1988 to 1993. All received a uniform preparative regimen of cyclophosphamide, BCNU and etoposide (CBV). Twenty-one percent had low grade histologies, 54% intermediate grade, and 25% high grade. Median follow-up of 48 survivors is 100 months. Kaplan-Meier 10 year overall survival and relapse-free survival for the entire group is 42% and 32%, respectively. Fifty patients were in complete remission 2 years post transplant. With additional follow-up, patients with high grade malignancies are cured, while patients with intermediate or low grade histologies were at continued risk of relapse up to 5 years post transplant. Of 39 patients in complete remission 5 years post transplant, none have relapsed with additional extended follow-up. We conclude that patients with NHL treated with ABMT, if in CR 5 years post transplant, are at very low risk of relapse with extended follow-up, suggesting the possibility of cure for all histologies, including those with low grade NHL.
Department of Hematology and Medical Oncology, Taussig Cancer Center, and Transplant Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R32, Cleveland, Ohio 44195, USA.
B
B
Bolwell
M
M
Kalaycio
R
R
Sobecks
S
S
Andresen
M
M
Mcbee
L
L
Kuczkowski
L
L
Rybicki
B
B
Pohlman
D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014182:Transplantation, Autologous